David Lanfear M.D. M.S.

DL pic
Investigator
Phone: (313) 874-5454
Fax: (313) 874-7137

Biography

David E. Lanfear, M.D., M.S., is Head of the Advanced Heart Failure and Transplant Cardiology section at Henry Ford Hospital in Detroit, and is also a Research Scientist in the Center for Health Services Research and Professor of Medicine at Wayne State University. Dr. Lanfear earned his medical degree from the University of Michigan Medical School, with residency and fellowship at Barnes-Jewish Hospital/Washington University in St. Louis, and is board certified in Cardiovascular Disease and Advanced Heart Failure and Transplant Cardiology. As Head of Advanced Heart Failure Dr. Lanfear oversees all the clinical, education, and research activity of the Section which encompasses the Heart Transplant and LVAD programs as well an advanced Fellowship and extensive clinical trial activities. Dr. Lanfear is also an independent researcher with a track record of NIH funded projects focused on precision medicine and genomics in heart failure. He has more than 100 published manuscripts, most either as first or senior author, reaching high-impact journals including JAMA, JACC, and Circulation:Heart Failure. Dr. Lanfear is an Associate Editor at Circulation:Heart Failure and has served in previously this role at Journal of Cardiac Failure and Heart Failure Reviews. He is also a national leader in academic societies having served on the ACC Heart Failure/Tx leadership committee, and serving currently on the HFSA Board of Directors, the AHA Genomics and Precision Medicine Leadership committee, and Chairing the ACC Young Investigators Award Committee, and recent appointments to ACC Accreditation Management Board and ACC Scientific Sessions Program Committee.

Recent publications

Sabbah HN, Gupta RC, Singh-Gupta V, Zhang K, Lanfear DE. Abnormalities of Mitochondrial Dynamics in the Failing Heart: Normalization Following Long-Term Therapy with Elamipretide. Cardiovasc Drugs Ther. 2018 Jun 27. doi: 10.1007/s10557-018-6805-y. [Epub ahead of print] PMID 29951944

Luzum JA, Peterson E, Li J, She R, Gui H, Liu B, Spertus JA, Pinto YM, Williams LK, Sabbah HN, Lanfear DE. Race and Beta-Blocker Survival Benefit in Patients With Heart Failure: An Investigation of Self-Reported Race and Proportion of African Genetic Ancestry. J Am Heart Assoc. 2018 May 8;7(10). JAHA.117.007956. PMID:29739794

Lanfear DE Joseph J Gibbs MD, Jia Li, Ruicong She, Christopher Petucci, Jeffrey A. Culver, W. H. Wilson Tang, Yigal M. Pinto, L. Keoki Williams, Hani N. Sabbah, and Stephen J. Gardell. Targeted Metabolomic Profiling of Plasma and Survival in Heart Failure Patients. JACC: Heart Failure In Press. Impact Factor: 8.5

Antoni Bayes-Genis*; David E Lanfear*; Maurice WJ de Ronde*; Josep Lupóna,b, MD, PhD; Joost J Leenders; Zhen Liu; Nicolaas PA Zuithoffg; Marinus JC Eijkemans; Elisabet Zamora; Marta De Antonio; Aeilko H Zwinderman; Sara-Joan Pinto-Sietsma; Yigal M Pinto. Prognostic value of circulating miRNAs on heart failure related morbidity and mortality in two large diverse cohorts of general heart failure patients. Euro J HF, In Press. Impact Factor: 6.98

Michael C. Kontos, David E. Lanfear, Kensey Gosch, Stacie L. Daugherty, Paul Heidenriech, and John A. Spertus. Prognostic Value Of Serial N Terminal-Pro Brain Natriuretic Peptide Testing in Patients With Acute Myocardial Infarction. Am J Cardiol, In Press Impact Factor: 3.154 Role: Interpretation of data, drafting and revision for important intellectual content

Lanfear DE, Levy WC, Stehlik J, Estep JD, Rogers JG, Shah KB, Boyle AJ, Chuang J, Farrar DJ, Starling RC. Accuracy of Seattle Heart Failure Model and HeartMate II Risk Score in non-inotrope dependent advanced heart failure patients: Insights from the ROADMAP study. Circulation: Heart Failure. 2017 10(5), e003745 Impact Factor: 7.2 Citations: 0 (Recently published)

Deronde MWJ, Ruijter JM, Lanfear DE, Bayes-Genis A, Kok MGM, Creemers EE, Pinto YM, and Pinto-Sietsma SJ. Practical data handling pipeline improves performance of qPCR-based circulating miRNA measurements. RNA 23:811–821 Impact Factor: N/A Citations: 0 Role: Interpretation of data, drafting and revision for important intellectual content

Mital S, Musunuru K, Garg V, Russell MW, Lanfear DE, Gupta RM, Hickey KT, Ackerman MJ, Perez MV, Roden DM, Woo D, Fox CS, Ware S; Enhancing Literacy in Cardiovascular Genetics: A Scientific Statement From the American Heart Association. American Heart Association Council on Functional Genomics and Translational Biology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Stroke Council; Council on Lifestyle and Cardiometabolic Health; and Council on Quality of Care and Outcomes Research. Circ Cardiovasc Genet. 2016 Oct;9(5):448-467. PMID: 27672144 Impact Factor: 3.808 Citations: 2 Role: Interpretation of data, drafting and revision for important intellectual content

Wells K, Cajigal S, Peterson, Peterson, E, Ahmedani B, Kumar R, Lanfear DE, Burchard E, Williams LK. Assessing differences in inhaled corticosteroid response by self-reported race-ethnicity and genetic ancestry among individuals with asthma. J Allergy Clin Immunol. 2016 May;137(5):1364-1369. PMID: 27016472 Impact Factor: 12.485 Citations: 2 Role: Interpretation of data, drafting and revision for important intellectual content

Lanfear DE, Li J, Abbas R, She R, Padhukasahasram B, Gupta RC, Langholz D, Tang WH, Williams LK, Sabbah HN, Chow SL. Genetic Factors Influencing B-type Natriuretic Peptide-Mediated Production of Cyclic Guanosine Monophosphate and Blood Pressure Effects in Heart Failure Patients. J Cardiovasc Transl Res. 2015 Dec;8(9):545-53. Impact Factor: 3.197